Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
PURPOSE
Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored.


Materials and Methods
Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectiveswere exploration of safety and analysis of eribulin efficacy (progression-free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered.


RESULTS
Median eribulin treatment duration was 3.3 months for the 250 patients included in this prospective single-arm study. Two hundreds and thirty-nine patients (95.6%) experienced an adverse event (AE) related to treatment including 129 (51.6%) with grade ≥ 3 AEs. The most frequently observed toxicities were cytopenias (59.6% of included patients), gastrointestinal disorders (59.2%), and asthenia (56.4%). The most frequent grade 3-4 AE was neutropenia (37.2% with 4.8% febrile neutropenia). Median PFS and OS were 4.6 and 11.8 months, respectively. Patients classified as responders to the last microtubule-inhibiting therapy had a longer OS (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.51 to 0.94; p=0.017), and tended to display a better PFS (HR, 0.78; 95% CI, 0.58 to 1.04; p=0.086). OS improvement was still significant in multivariate analysis (adjusted HR, 0.53; 95% CI, 0.35 to 0.79; p=0.002).


CONCLUSION
This work based on a prospective study suggests that identification of patients likely to be more sensitive to eribulin could be based on their previous response to microtubules inhibitors.
['Sabatier|Renaud|R|', 'Diéras|Véronique|V|', 'Pivot|Xavier|X|', 'Brain|Etienne|E|', 'Roché|Henri|H|', 'Extra|Jean-Marc|JM|', 'Monneur|Audrey|A|', 'Provansal|Magali|M|', 'Tarpin|Carole|C|', 'Bertucci|François|F|', 'Viens|Patrice|P|', 'Zemmour|Christophe|C|', 'Gonçalves|Anthony|A|']
D000328:Adult D000368:Aged D001943:Breast Neoplasms D005260:Female D005602:France D005663:Furans D006801:Humans D007659:Ketones D008875:Middle Aged D009362:Neoplasm Metastasis D000077982:Progression-Free Survival D011446:Prospective Studies D012189:Retrospective Studies D016019:Survival Analysis D016896:Treatment Outcome D050257:Tubulin Modulators
Safety Eribulin Metastatic breast cancer Survival Microtubule inhibition